Loading... Please Wait
Become a part of our network dedicated to helping the people in our communities live healthier through access to high quality, affordable care.
Get StartedWe would like to share updates with you regarding preauthorization under our Utilization Management (UM) Program.
We are excited to share with you that we have a new grid available on our website to help you determine when we require dental records to consider or approve a claim for payment.
The U.S. Food and Drug Administration issued an emergency use authorization for investigational monoclonal antibody therapies bamlanivimab and casirivimab/imdevimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adult and pediatric patients.